Immunic, Inc. (IMUX)
Immunic to host virtual relapsing MS R&D Day on September 9
Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will feature Immunic management, including CEO Erik Lundgren, chief medical officer Michael Panzara, chief scientific officer Hella Kohlhof and president and chief operating officer Jason Tardio.
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating
Immunic is advancing vidofludimus calcium (IMU-838) in late-stage trials for both relapsing and progressive multiple sclerosis. MS represents a substantial market, with existing therapies projected to reach ~$22 billion in 2026 revenues. IMU-838's oral administration and differentiated mechanism of action position it as a potential major player in the MS market.
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Immunic (IMUX) points to a 163% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunic advances MS drug toward key Phase 3 data, expects results by year-end
Immunic Inc (NASDAQ:IMUX, FRA:10VA) is preparing for a series of clinical and corporate milestones as it advances its lead drug candidate vidofludimus calcium through late-stage development in multiple sclerosis, while expanding its leadership team ahead of potential regulatory filings and commercialization. The biotechnology company reported second-quarter results on Tuesday and said its Phase 3 ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium in relapsing multiple sclerosis remain on track to deliver top-line data by the end of 2026.
Immunic presents new vidofludimus calcium data at multiple sclerosis conference
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Thursday it presented three posters at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting in Charlotte, North Carolina, including a late-breaking analysis of its lead drug candidate vidofludimus calcium in patients with progressive multiple sclerosis. The late-breaking poster introduced a novel unified endpoint called Confirmed Disability Change, designed to capture both disability worsening and improvement within a single statistical framework.
FTSE 100 Live: Global markets hit record highs, oil prices slide as Iran deal awaited
FTSE 100 up 13 points at 10,505 Asian and US tech stocks drive new global markets to all-time highs Energy prices and govt bonds ease on Iran optimism UK...
Immunic names Erik Lundgren as CEO as it advances Phase 3 MS trials
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named biopharmaceutical executive Erik Lundgren as its chief executive officer as the company advances its multiple sclerosis treatment candidate through late-stage development and prepares for potential commercialization. He succeeds Daniel Vitt, who will continue to oversee scientific strategy and portfolio advancement while remaining on the company's board of directors.
Immunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readout
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including a background in multiple sclerosis and central nervous system markets.
Immunic advances Phase 3 MS program, eyes topline data by year-end
Immunic Inc (NASDAQ:IMUX, FRA:10VA) said on Wednesday it remains on track to deliver top-line phase 3 data for its lead multiple sclerosis drug candidate, vidofludimus calcium, by the end of 2026, as the company strengthens its leadership team and bolsters its balance sheet with a recently completed $200 million private financing. Along with the release of its first quarter financial results, the biotechnology company said it continues to advance its twin phase 3 ENSURE-1 and ENSURE-2 trials evaluating vidofludimus calcium in relapsing multiple sclerosis (RMS).
Immunic: Saved By A 200 Million Private Placement
Immunic, Inc. (IMUX) is rated Hold due to high cash burn, heavy dilution, and reliance on a single near-term catalyst. Vidofludimus calcium (IMU-838) Phase 3 MS trial results, expected late 2026, are pivotal for IMUX's future revenue and valuation. Recent $187M private placement and $200M in warrants extend IMUX's cash runway to Phase 3 readout, and hopefully to the drugs rollout to the market, reducing near-term dilution risk.
Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout
Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Michael A. Panzara as Chief Medical Officer, bringing aboard a veteran neurologist with more than 25 years of drug development experience as the biotechnology company braces for a critical clinical milestone in multiple sclerosis.
Immunic to implement 1-for-10 reverse stock split
Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced it will implement a 1-for-10 reverse stock split of its common shares, effective April 27, as part of efforts to meet contractual obligations tied to a recent securities agreement. The reverse split will take effect at 12:01 a.m.
